Interview with Two Key People of the Fight Against Lupus

06/05/2016 - 1 minute

I was in Paris this week in the building of the Rare Disease Alliance, an association helping patients affected by a rare disease. The association lend their space to Neovacs, a biotech company from Paris, which was organising a gathering of experts of lupus.

neovacs_logo_immunotherapy_lupus_stellarLupus is one of the most common rare disease and affects more than 5 million people worldwide. This meet-up was a good opportunity for me to talk with Prf. Jean Sibilia,  Head of the National Reference Centre for Systemic Autoimmune Diseases and Miguel Sieler, CEO of Neovacs which develops a drug candidate against this disease.

 

Learn more in the video below!Please accept preferences cookies to watch this video.

More on Neovacs in these articles from Labiotech.eu:

Want to know more?

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member